The potential of somatostatin receptor 2 as a novel therapeutic target in salivary gland malignant tumors



Treatment regimens for patients with metastatic or recurrent post-radiation, locoregional, unresectable salivary cancer are limited. An inverse correlation between somatostatin receptor 2 (SSTR2) and the proliferating marker Ki-67 in neuroendocrine tumors has enabled a treatment plan for metastatic disease, utilizing peptide receptor radionuclide therapy. Interestingly, healthy salivary glands express high levels of SSTR2. In this study, the presence of SSTR2, its correlation with Ki-67 in glandular salivary carcinomas and the clinical applicability thereof was determined.


In the retrospective part of this study, 76 adequate tumor tissue specimens obtained from patients diagnosed with primary or metastatic salivary carcinomas between 1988 and 2016, were collected for tissue array and histologically classified. Immunohistochemistry was performed to determine the presence, relative expression and potential correlation of SSTR2 and Ki-67. The clinical significance of SSTR2 expression was determined by prospectively assessing 68Ga-DOTATATE uptake using PET-CT imaging, in patients diagnosed with metastatic salivary gland malignant tumors between 2015 and 2016.


Sixty-three primary cancer tumors and 14 metastatic tumors were tested. All tumor subtypes were found to express SSTR2 to some extent. The highest expression was seen in Mucoepidermoid carcinoma (MEC) tissues where the majority of specimens (86.4%) expressed SSTR2. A relatively strong immunohistochemical staining score for SSTR2 was observed in MEC, adenoid cystic carcinoma and polymorphous adenocarcinoma. Interestingly, an inverse correlation between SSTR2 and Ki-67 expressions was observed (44%) in MEC tissue. Uptake of 68Ga-DOTATATE was visualized using PET-CT imaging in 40% of patients, across metastatic MEC and ACC. All observations were found to be statistically significant.


This study confirms the expression of SSTR2 in glandular salivary carcinomas and an inverse correlation in expression levels between SSTR2 and Ki-67. This lays a foundation for novel treatment options in salivary metastatic cancers where SSTR2 may be a potential novel therapeutic target.

This is a preview of subscription content, access via your institution.

Fig. 1

Code availability

Not applicable.

Availability of data and material

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.


  1. Bodei L, Pepe G, Paganelli G (2010) Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur Rev Med Pharmacol Sci 14:347–351

    CAS  PubMed  Google Scholar 

  2. Chang JW, Hong HJ, Ban MJ, Shin YS, Kim WS, Koh YW, Choi EC (2015) Prognostic factors and treatment outcomes of parotid gland cancer: a 10-year single-center experience. Otolaryngol Head Neck Surg 153:981–989

    Article  Google Scholar 

  3. Chatura K (2015) Polymorphous low grade adenocarcinoma. J Oral Maxillofac Pathol 19:77

    CAS  Article  Google Scholar 

  4. Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT (2016) Safety and efficacy of 68Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. J Nucl Med 57:708–714

    CAS  Article  Google Scholar 

  5. El-Naggar AK, Chan JK, Grandis JR, Takata T, Slootweg PJ (2017) WHO classification of head and neck tumours. International Agency for Research on Cancer, France

    Google Scholar 

  6. Gaissert HA, Mark EJ (2006) Tracheobronchial gland tumors. Cancer Control 13:286–294

    Article  Google Scholar 

  7. Gupta R, Balasubramanian D, Clark JR (2015) Salivary gland lesions: recent advances and evolving concepts. Oral Surg Oral Med Oral Pathol Oral Radiol 119:661–674

    Article  Google Scholar 

  8. Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L (2010) Major and minor salivary gland tumors. Crit Rev Oncol Hematol 74:134–148

    Article  Google Scholar 

  9. Ho K, Lin H, Ann DK, Chu PG, Yen Y (2011) An overview of the rare parotid gland cancer. Head Neck Oncol 3:40

    Article  Google Scholar 

  10. Hofland L, Liu Q, van Koetsveld P, Zuijderwijk J, van der Ham F, de Krijger R, Schonbrunn A, Lamberts S (1999) Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. J Clin Endocrinol Metab 84:775–780

    CAS  Article  Google Scholar 

  11. Lagha A, Chraiet N, Ayadi M, Krimi S, Allani B, Rifi H, Raies H, Mezlini A (2012) Systemic therapy in the management of metastatic or advanced salivary gland cancers. Oral Oncol 48:948–957

    CAS  Article  Google Scholar 

  12. Møller LN, Stidsen CE, Hartmann B, Holst JJ (2003) Somatostatin receptors. Biochim Biophy Acta (BBA) Biomembr 1616:1–84

    Article  Google Scholar 

  13. Namboodiripad PA (2014) A review: immunological markers for malignant salivary gland tumors. J Oral Biol Craniofac Res 4:127–134

    Article  Google Scholar 

  14. Reubi J, Laissue J, Krenning E, Lamberts S (1992) Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 43:27–35

    CAS  Article  Google Scholar 

  15. Shastry M, Kayani I, Wild D, Caplin M, Visvikis D, Gacinovic S, Reubi JC, Bomanji JB (2010) Distribution pattern of 68Ga-DOTATATE in disease-free patients. Nucl Med Commun 31:1025–1032

    Article  Google Scholar 

  16. Spiro RH (1986) Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 8:177–184

    CAS  Article  Google Scholar 

  17. Spiro RH (1997) Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg 174:495–498

    CAS  Article  Google Scholar 

  18. Stenner M, Molls C, Luers JC, Beutner D, Klussmann JP, Huettenbrink K-B (2012) Occurrence of lymph node metastasis in early-stage parotid gland cancer. Eur Arch Otorhinolaryngol 269:643–648

    Article  Google Scholar 

  19. Taniyama Y, Suzuki T, Mikami Y, Moriya T, Satomi S, Sasano H (2005) Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J 52:605–611

    CAS  Article  Google Scholar 

  20. Terhaard CH, Lubsen H, van der Tweel I, Hilgers F, Eijkenboom W, Marres H, Tjho-Heslinga R, de Jong J, Roodenburg J (2004) Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck J Sci Special Head Neck 26:681–693

    Article  Google Scholar 

  21. Theodoropoulou M, Stalla GK (2013) Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 34:228–252

    CAS  Article  Google Scholar 

  22. Vasconcelos AC, Nör F, Meurer L, Salvadori G, Souza LBD, Vargas PA, Martins MD (2016) Clinicopathological analysis of salivary gland tumors over a 15-year period. Brazilian Oral Research 30:S1806

    Article  Google Scholar 

  23. Volante M, Brizzi MP, Faggiano A, la Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20:1172–1182

    CAS  Article  Google Scholar 

  24. Wang L, Tang K, Zhang Q, Li H, Wen Z, Zhang H, Zhang H (2013) Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors. BioMed Res Int 2013:102819

    PubMed  PubMed Central  Google Scholar 

  25. Wang X, Luo Y, Li M, Yan H, Sun M, Fan T (2017) Management of salivary gland carcinomas—a review. Oncotarget 8:3946

    Article  Google Scholar 

  26. Watanabe K, Okumura Y, Hashimoto K, Suzuki T (2015) Clear cell carcinoma of the base of the tongue: case report and literature review. Ann Otol Rhinol Laryngol 124:55–61

    Article  Google Scholar 

  27. Zhan KY, Lentsch EJ (2016) Basal cell adenocarcinoma of the major salivary glands: a population-level study of 509 cases. Laryngoscope 126:1086–1090

    Article  Google Scholar 

Download references


This study has not been externally funded.

Author information




Amichay Meirovitz: study design, conduction, data analysis and manuscript preparation. Karny Blum: pathological and histological analysis and manuscript preparation. Alexander Maly: pathological and histological analysis. Evgeniya Bersudski: sample collection. Nir Hirshoren: sample collection. Ross Abrams: data analysis and manuscript preparation. Aron Popovtzer: data analysis and manuscript preparation. Marina Orevi: nuclear medicine analysis. Jeffrey Weinberger: study design and manuscript preparation.

Corresponding author

Correspondence to Amichay Meirovitz.

Ethics declarations

Conflict of interest

None of the authors have any conflicts of interest to declare.

Ethics approval

Declaration of Helsinki approval: approval no. 0421-15-HMO.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent for publication

Only non-identifying participant data will be published.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Meirovitz, A., Blum, K.S., Maly, A. et al. The potential of somatostatin receptor 2 as a novel therapeutic target in salivary gland malignant tumors. J Cancer Res Clin Oncol (2021).

Download citation


  • Salivary carcinomas
  • Somatostatin receptor
  • Ki-67
  • Peptide receptor radionuclide therapy
  • PET-CT